Mainz Biomed N.V. announced its intention to provide an interim readout of its eAArly DETECT 2 feasibility study by the end of summer 2025. This study is evaluating the company’s next-generation colorectal cancer (CRC) screening test.
The eAArly DETECT 2 study integrates Mainz Biomed's proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test, involving approximately 2,000 average-risk patients. Top-line results for the study are still anticipated in the fourth quarter of 2025.
This interim update indicates continued progress in the clinical trial, which remains on track to support the initiation of the ReconAAsense U.S. pivotal study in 2026. The study aims to validate previous results and advance the detection of precancerous adenomas and early-stage CRC.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.